课题基金 / 基金详情

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center

Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center
参议员 Paul D. Wellstone 肌营养不良症合作研究中心
批准号:
8333446
负责人:
RICHARD J SAMULSKI
金额:
$139.17万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-09-05 至 2014-02-28

项目摘要

项目成果

RICHARD J SAMULSKI的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The NIH Senator Paul B. Wellstone Centers are the centerpiece of the nation's effort to reduce morbidity and mortality from muscular disorders and are a major source of discovery and development of more effective approaches to prevention, diagnosis, and therapy. The University of North Carolina (UNC) "goal" of establishing a premier Wellstone Center in the state of North Carolina has assembled a highly interactive research group creating a dynamic program comprised of experienced clinical investigators (Drs. Powers & Wolff), expert basic laboratories (Drs. Samulski, Xiao, and Beecham), and large animal models (Dr. Kornegay) focused on developing, testing, and establishing therapeutic treatments for Duchenne Muscular Dystrophy (DMD) and other genetic muscle disorders. A major theme of the Center is to advance novel gene based therapies into the clinic for muscle disorders. The impetus for this effort stems from the fact that UNC Gene Therapy Center (GTC) has made significant strides in recent years to build the foundation that will enable development of a full-scale bench-to-bedside effort bringing gene therapy for DMD closer to a reality (e.g. GMP vector production facility, DMD dog model core). In the spirit of this mission, UNC with support from MDA has independently initiated the first gene-based therapy for DMD using a newly engineered AAV vector (Dr. Samulski) and a mini-dystrophin (dys) gene (Dr. Xiao). A common theme emerging from our Phase I studies and a primary focus of the proposal, relates to establishing a clear understanding of safety and efficacy after treatment with gene based therapeutics and advancing these efforts into selected human clinical trials that will show potential for treatment. Continued discussion with FDA for most efficient and prudent manner to advance our gene therapy based efforts to DMD patients with minimum risk and maximum benefit has lead to the proposed MDCRC Wellstone Center application. The MDCRC will consist of 3 projects (Project 1 PI- Dr. Powers coPI Dr. Wolff -, Project 2 PI-Dr. Xiao, Project 3 PI- Dr. Samulski, (Projects 1-3) and four cores: an Administrative core (PI-Dr. Jude Samulski, Co-PI-Dr. Powers) Training Core, Vector Core (PI Dr. Jeffrey Beecham) and Large animal core (PI- Dr. Kornegay).
期刊论文(8)
专著(0)
科研奖励(0)
会议论文
K137R mutation on adeno-associated viral capsids had minimal effect on enhancing gene delivery in vivo.
腺相关病毒衣壳上的 K137R 突变对增强体内基因递送的影响极小。
DOI: 10.1089/hgtb.2013.176
发表时间: 2014
期刊: Human gene therapy methods
影响因子: --
作者: [Qiao,Chunping, Li,Chengwen, Zhao,Chunxia, Li,Jianbin, Bian,Tao, Grieger,Joshua, Li,Juan, Samulski,RJude, Xiao,Xiao]
通讯作者: Xiao,Xiao
Intravenous thrombolysis of basilar artery thrombosis.
基底动脉血栓的静脉溶栓。
DOI: 10.1002/ana.24062
发表时间: 2014
期刊: Annals of neurology
影响因子: 11.2
作者: [Powers,WilliamJ]
通讯作者: Powers,WilliamJ
DOI: 10.1016/j.nbd.2011.09.014
发表时间: 2012-11
期刊: NEUROBIOLOGY OF DISEASE
影响因子: 6.1
作者: [Lentz, Thomas B., Gray, Steven J., Samulski, R. Jude]
通讯作者: Samulski, R. Jude
Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector.
重组腺相关病毒:作为基因治疗载体的临床应用和开发。
DOI: 10.4155/tde.12.63
发表时间: 2012
期刊: Therapeutic delivery
影响因子: 4.2
作者: [Xiao,Ping-Jie, Lentz,ThomasB, Samulski,RJude]
通讯作者: Samulski,RJude
Neutralizing Antibody & AAV FIX Gene Therapy
Neutralizing Antibody & AAV FIX Gene Therapy
Development of Human beta cell-specific AAV Vectors for Type I Diabetes
Development of Human beta cell-specific AAV Vectors for Type I Diabetes
海外基金